A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a global, phase 3, randomized, double‐blind, parallel‐group, 2‐arm, placebocontrolled, multicenter trial designed to compare the efficacy, safety and tolerabilityof a fixed dose of SEP‐363856 (75 millligrams per day [mg/day]) to placebo over an 8‐weekdouble‐blind treatment period in adults with generalized anxiety disorder (GAD).
Epistemonikos ID: ac1de785cdb11cc75daf1a29c4824849790c3a3a
First added on: Aug 17, 2026